Estimating the burden of adult hospitalized RSV infection using local and state data - methodology
- PMID: 35271432
- PMCID: PMC8920185
- DOI: 10.1080/21645515.2021.1958610
Estimating the burden of adult hospitalized RSV infection using local and state data - methodology
Abstract
Respiratory syncytial virus (RSV) is becoming increasingly recognized as a serious threat to vulnerable population subgroups. This study describes the statistical analysis plan for a retrospective cohort study of adults hospitalized for acute respiratory infection (ARI) to estimate the population burden of RSV especially for groups such as the elderly, pregnant women and solid organ transplant patients. Disease burden estimates are essential for setting vaccine policy, e.g., should RSV vaccine become available, burden estimates may inform recommendations to prioritize certain high-risk groups. The study population is residents of Allegheny County, Pennsylvania ≥18 years of age who were hospitalized in Pennsylvania during the period September 1, 2015-August 31, 2018. Data sources will include U.S. Census, Pennsylvania Health Care Cost Containment Council (PHC4) and the electronic medical record for the health system to which the hospitals belong. The algorithm involves: 1) ARI-associated hospitalizations in PHC4 data; 2) adjustment for ARI hospitalizations among county residents but admitted to hospitals outside the county; and 3) RSV detections from respiratory viral panels. Key sensitivity analyses will adjust for undertesting for viruses in the fall and spring quarters. The results will be population-based estimates, stratified by age and risk groups. Adjusting hospitalization data using a multiplier method is a simple means to estimate the impact of RSV in a given area. This algorithm can be applied to other health systems and localities to estimate RSV and other respiratory pathogen burden in adults, to estimate burden following introduction of RSV vaccine and to make cost-effectiveness estimates.
Keywords: RSV burden; acute respiratory illness; adults; retrospective cohort study; statistical analysis plan.
Similar articles
-
Estimating the burden of adult hospitalized RSV infection including special populations.Vaccine. 2022 Jul 29;40(31):4121-4127. doi: 10.1016/j.vaccine.2022.05.077. Epub 2022 Jun 3. Vaccine. 2022. PMID: 35667912 Free PMC article.
-
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.Expert Rev Vaccines. 2024 Jan-Dec;23(1):303-311. doi: 10.1080/14760584.2024.2323128. Epub 2024 Mar 1. Expert Rev Vaccines. 2024. PMID: 38426479
-
Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model.Clin Infect Dis. 2023 Aug 14;77(3):480-489. doi: 10.1093/cid/ciad161. Clin Infect Dis. 2023. PMID: 36949605
-
Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis.J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583. doi: 10.1093/infdis/jiz059. J Infect Dis. 2020. PMID: 30880339
-
Burden of Respiratory Syncytial Virus-Associated Acute Respiratory Infections During Pregnancy.J Infect Dis. 2024 Mar 1;229(Supplement_1):S51-S60. doi: 10.1093/infdis/jiad449. J Infect Dis. 2024. PMID: 37824420
Cited by
-
Population-based hospitalization burden estimates for respiratory viruses, 2015-2019.Influenza Other Respir Viruses. 2022 Nov;16(6):1133-1140. doi: 10.1111/irv.13040. Epub 2022 Aug 22. Influenza Other Respir Viruses. 2022. PMID: 35996836 Free PMC article.
-
Late diagnosis of respiratory syncytial virus and influenza co-infection during coronavirus disease 2019 pandemic: a case report.J Med Case Rep. 2023 Oct 21;17(1):437. doi: 10.1186/s13256-023-04187-3. J Med Case Rep. 2023. PMID: 37864237 Free PMC article.
-
Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019.Infect Dis Ther. 2024 Apr;13(4):845-860. doi: 10.1007/s40121-024-00951-0. Epub 2024 Mar 23. Infect Dis Ther. 2024. PMID: 38520629 Free PMC article.
-
Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database.Pharmacoecon Open. 2025 May;9(3):445-459. doi: 10.1007/s41669-025-00565-3. Epub 2025 Mar 19. Pharmacoecon Open. 2025. PMID: 40108096 Free PMC article.
-
Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis.Gene Ther. 2025 Jan;32(1):38-49. doi: 10.1038/s41434-023-00385-2. Epub 2023 Feb 2. Gene Ther. 2025. PMID: 36732618
References
-
- Karron RA. Respiratory syncytial virus and parainfluenza virus vaccines. In: Plotkin Stanley A, Orenstein Walter A, Offit Paul A, editors. Vaccines. 6th ed. Elsevier; 2013. p.1146–12.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical